GlassScriptPhysician profile
Ernesto Cardenas
NPI 1073568143
$5,607.88
in general payments reported to CMS, 2019-2025
24 companies · $449 in 2025
The $449 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $428 · 2021: $500 · 2022: $1,030 · 2023: $2,648 · 2024: $263 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $1,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $1,360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $2,060.68 | 2023-2024 | Slynd, Tyblume |
| Ethicon US, LLC | $948.17 | 2019-2025 | Ethicon, Evarrest, Harmonic |
| Mayne Pharma Commercial LLC | $584.41 | 2021-2025 | |
| Abbvie INC. | $576.47 | 2019-2023 | Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $459.56 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Coopersurgical, INC. | $236.17 | 2021-2025 | Paragard T 380a, Paragard T 380a, Ally II Ups |
| Avion Pharmaceuticals | $134.58 | 2019-2021 | |
| Medical Device Business Services, INC. | $119.11 | 2022 | |
| Shield Therapeutics INC | $91.76 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $78.63 | 2019-2023 | |
| Therapeuticsmd, INC. | $41.51 | 2022 | |
| Organon LLC | $41.46 | 2022-2024 | |
| Ge Healthcare | $36.30 | 2020 | |
| Daiichi Sankyo INC. | $26.75 | 2022 | |
| Pfizer INC. | $23.78 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20.87 | 2024 | Veozah |
| Millicent US INC | $19.84 | 2025 | Femlyv, Intrarosa |
| Evofem Biosciences, INC. | $18.33 | 2024 | |
| Allergan, INC. | $17.38 | 2019 | |
| Axonics, INC. | $17.20 | 2021 | |
| Merck Sharp & Dohme LLC | $14.11 | 2020 | |
| Optumhealth Care Solutions, LLC | $14.11 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Covidien LP | $13.67 | 2019 | |
| Caldera Medical, INC | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernesto Cardenas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.